EIT Health Belgium-Netherlands awards VitroScan with HeadStart Funding

29 August 2018

Establishing a Drug Response Platform - The selection was made from 28 high quality proposals

Vitroscan’s platform offers drug developers a tool to test novel drugs in series of cancer patients, to compare the response with standard care drugs and to characterise responsive patients in detail (clinical response, genetic analysis) thus improving the outcome of subsequent clinical trials. 

HeadStart Funding supports start-ups in taking their next step to the market by accelerating market entry and by creating new economic activity more effectively. In addition to the €50 000 cash award, EIT Health and its partners provide access to innovation facilities and networks as well as mentoring. Moreover, the grant will increase the possibility of attracting further private investment.